<?xml version="1.0" encoding="UTF-8"?>
<p>WNV is widely distributed in Africa, Europe, Australia, and Asia. Since its detection in New York City in 1999 [
 <xref rid="B37-molecules-25-02796" ref-type="bibr">37</xref>], it continued to spread throughout the Western hemisphere—including other parts of USA, Canada, Mexico, and the Caribbean—resulting in significant morbidity and mortality [
 <xref rid="B38-molecules-25-02796" ref-type="bibr">38</xref>]. WNV is maintained in nature in a mosquito-bird-mosquito transmission cycle, primarily involving 
 <italic>Culex</italic> spp. mosquitoes and humans, horses, and other mammals are incidental hosts [
 <xref rid="B39-molecules-25-02796" ref-type="bibr">39</xref>]. Most individuals infected with WNV are asymptomatic and ~20% of infected persons will experience clinical symptoms [
 <xref rid="B40-molecules-25-02796" ref-type="bibr">40</xref>]. The majority of people with symptoms will develop West Nile fever, and only a small number will progress to severe West Nile neuroinvasive disease (WNND), which is potentially fatal (less than 1% of all infected people) [
 <xref rid="B41-molecules-25-02796" ref-type="bibr">41</xref>]. Serious manifestations of WNND include encephalitis, meningitis, and acute flaccid paralysis [
 <xref rid="B42-molecules-25-02796" ref-type="bibr">42</xref>]. Additionally, some patients suffer fatigue, muscle weakness, and persistent tremors, lasting weeks to years even after recovery [
 <xref rid="B43-molecules-25-02796" ref-type="bibr">43</xref>,
 <xref rid="B44-molecules-25-02796" ref-type="bibr">44</xref>,
 <xref rid="B45-molecules-25-02796" ref-type="bibr">45</xref>]. Unfortunately, only supportive treatment is available for patients who suffer from severe and debilitating effects of WNND. To date, vaccines against WNV have been developed for horses [
 <xref rid="B17-molecules-25-02796" ref-type="bibr">17</xref>,
 <xref rid="B18-molecules-25-02796" ref-type="bibr">18</xref>], but there are no available vaccines for human use.
</p>
